{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:54:55Z","timestamp":1781826895499,"version":"3.54.5"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Suzetrigine (JOURNAVX\u00ae) is a novel non-opioid pain medication that was approved in January 2025. Given the well-documented abuse potential of opioids, suzetrigine may become more widely prescribed as an alternative for acute pain management. However, it could still appear in forensic casework as little is understood about its role in polydrug toxicity, comorbidity with pre-existing health conditions, or abuse potential within larger populations. As such, this research aimed to develop the first forensically focused method to detect suzetrigine in blood and urine. Due to its similar physicochemical properties, suzetrigine was seamlessly integrated into a previously validated liquid\u2013liquid extraction method developed for novel dual orexin receptor antagonists (DORAs). This report focuses on the subsequent method development and validation for suzetrigine detection using liquid chromatography\u2013tandem mass spectrometry (LC\u2013MS\/MS). The method was validated in accordance with ANSI\/ASB 036 for the quantification of suzetrigine in blood and its qualitative identification in urine. A quadratic calibration model with 1\/x weighing was utilized (1.0\u20131000\u2009ng\/ml) with quality controls (QCs) at 1.5, 80, 400, and 800\u2009ng\/ml. The limit of detection in blood and urine was 0.25\u2009ng\/ml, while the limit of quantitation in blood was 1.0\u2009ng\/ml. Post-extraction addition at 5 and 500\u2009ng\/ml yielded matrix effects less than \u00b125%, but increased variability at the low concentration in blood was deemed to have no impact on LOD. No carryover or interferences were observed from the internal standard, matrices, or common drugs. Dilution integrity (5X) was acceptable in blood, and processed samples were stable up to 72\u2009hours in the autosampler. In this report we describe a simple extraction for suzetrigine in blood and urine followed by LC\u2013MS\/MS analysis. This analytical workflow will be valuable as the use of suzetrigine becomes more prevalent in casework samples.<\/jats:p>","DOI":"10.1093\/jat\/bkag041","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:28:57Z","timestamp":1781004537000},"source":"Crossref","is-referenced-by-count":0,"title":["Analysis of suzetrigine, a novel nonopioid pain medication, in whole blood and urine using liquid chromatography\u2013tandem mass spectrometry"],"prefix":"10.1093","volume":"50","author":[{"given":"Isabelle R","family":"Parry","sequence":"first","affiliation":[{"name":"Department of Forensic Science, College of Criminal Justice, Sam Houston State University , Huntsville, TX 77340,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0142-2286","authenticated-orcid":false,"given":"Britni N","family":"Skillman","sequence":"additional","affiliation":[{"name":"Department of Forensic Science, College of Criminal Justice, Sam Houston State University , Huntsville, TX 77340,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"2026061819383718600_bkag041-B1","author":"U.S. Centers for Disease Control (CDC)","year":"2025"},{"key":"2026061819383718600_bkag041-B2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: development, challenges and opportunities","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol Psychiatry"},{"key":"2026061819383718600_bkag041-B3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/bs.apha.2021.09.002","article-title":"Potential therapeutic targets for the treatment of opioid abuse and pain","volume":"93","author":"Kiguchi","year":"2022","journal-title":"Adv Pharmacol ("},{"key":"2026061819383718600_bkag041-B4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40122-024-00697-0","article-title":"Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain","volume":"14","author":"Osteen","year":"2025","journal-title":"Pain Ther"},{"key":"2026061819383718600_bkag041-B5","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s11916-024-01295-7","article-title":"Frontiers in acute pain management: emerging concepts in pain pathways and the role of VX-548 as a novel NaV1.8 inhibitor: a narrative review","volume":"28","author":"Kaye","year":"2024","journal-title":"Curr Pain Headache Rep"},{"key":"2026061819383718600_bkag041-B6","author":"Food and Drug Administration (FDA)","year":"2025"},{"key":"2026061819383718600_bkag041-B7","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.2147\/JPR.S526851","article-title":"Suzetrigine approval breaks a 25-year silence: a new era in non-opioid acute pain management","volume":"18","author":"Sibomana","year":"2025","journal-title":"J Pain Res"},{"key":"2026061819383718600_bkag041-B8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2209870","article-title":"Selective inhibition of NaV 1.8 with VX-548 for acute pain","volume":"389","author":"Jones","year":"2023","journal-title":"N Engl J Med"},{"key":"2026061819383718600_bkag041-B9","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1097\/ALN.0000000000005460","article-title":"Suzetrigine, a nonopioid Na V 1.8 inhibitor for treatment of moderate-to-severe acute pain: two phase 3 randomized clinical trials","volume":"142","author":"Bertoch","year":"2025","journal-title":"Anesthesiology"},{"key":"2026061819383718600_bkag041-B10","author":"Vertex Pharmaceuticals","year":"2025"},{"key":"2026061819383718600_bkag041-B11","first-page":"214","article-title":"Benzodiazepine pharmacology and central nervous system\u2013mediated effects","volume":"13","author":"Griffin","year":"2013","journal-title":"Ochsner J"},{"key":"2026061819383718600_bkag041-B12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/jat\/bkaf032","article-title":"Quantification of daridorexant, lemborexant, and suvorexant in whole blood using liquid chromatography\u2013tandem mass spectrometry","volume":"49","author":"Gomonit","year":"2025","journal-title":"J Anal Toxicol"},{"key":"2026061819383718600_bkag041-B13","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.5664\/jcsm.7282","article-title":"An update on dual orexin receptor antagonists and their potential role in insomnia therapeutics","volume":"14","author":"Janto","year":"2018","journal-title":"J Clin Sleep Med"},{"key":"2026061819383718600_bkag041-B14","author":"Academy Standards Board","year":"2019"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkag041\/68495424\/bkag041.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/50\/6\/bkag041\/68495424\/bkag041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/50\/6\/bkag041\/68495424\/bkag041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:38:44Z","timestamp":1781825924000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/doi\/10.1093\/jat\/bkag041\/8704551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkag041","relation":{},"ISSN":["1945-2403"],"issn-type":[{"value":"1945-2403","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"bkag041"}}